The BIA’s Board is drawn from a wide range of member companies. The Board currently comprises 15 Members, each of whom has been elected for a three-year term, after which they are invited to put themselves forward for re-election.
Dr Jane Osbourn
Jane is a phage and ribosome display expert with significant experience in antibody engineering and drug discovery, and has generated several key publications and patents. She joined MedImmune, formerly Cambridge Antibody Technology (CAT), in September 1993 and initially focused on building large phage antibody libraries. Jane then worked within antibody generation teams, subsequently leading CAT’s technology development and making a significant contribution to the company’s research capabilities. From 2005 to 2007 she managed CAT’s oncology portfolio. Following the integration with MedImmune in 2007 Jane led the Research Department at the Cambridge site, becoming Site Leader for MedImmune Cambridge in July 2008. Additionally, after a period as Centre of Excellence leader within MedImmune’s cardio-vascular/metabolic disease team, in March 2011 Jane took on the leadership of new opportunities biologics team and is now managing the biosuperiors portfolio which is focused on creating differentiated biologics drugs addressing clinically validated targets.
Jane won the IODs’ East of England Business Woman of the Year Award in recognition of her contribution to the successful integration and development of CAT and MedImmune.
The MedImmune team has become part of the new Astra Zeneca R&D hub based in Cambridge. Jane has been active in supporting this initiative and built strong links between MedImmune/AZ and the Cambridge science and business communities.
Eva-Lotta joined Immunocore as Chief Business Officer in May 2013. She has over 25 years of business development experience from the biotechnology and life science industry in both private and public companies, and is an elected member of the BioIndustry Association (BIA) Board of Directors. She is also on the Board of Targovax ASA. Eva-Lotta was previously at Ablynx NV, where she served as Chief Business Officer from 2006. Prior to Ablynx, Eva-Lotta served as Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals and before that held senior positions at Oxford Asymmetry International plc (now part of Evotec) and Oxford GlycoSystems. She received her degree in microbiology from the University of Stockholm.
Dr Charles Brigden
Charles joined BTG in May 2014 and is responsible for all aspects of global Corporate Business Development as part of the company Leadership Team.
Charles most recently held the position of Business Development and Licensing Director in Amgen’s Global Corporate Business Development group where he worked on multiple M&A and partnership transactions in Europe, the US and in various Emerging Markets. Charles was also board observer at Opsona Therapeutics, an Amgen Ventures portfolio company focused on research in the innate immune system. Before working in Business Development, Charles held a number of senior leadership positions in R&D, including Executive Medical Director for Amgen in the UK and Ireland, overseeing the late stage development and launch of numerous biotechnology products.
Previously, Charles worked as a Physician and Surgeon in the National Health Service, having qualified in Medicine at Bart’s and The Royal London Hospital Medical School. Charles is a Fellow of the Royal College of Surgeons, a member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and holds an MBA from Columbia and London Business Schools.
He assists the BIA in positioning the UK as a global biotechnology hub and as the best location for innovative research and commercialisation. He is also well positioned to promote the UK among the venture community as one of the best places in the world for life sciences investment.
Dr Jane Dancer
Jane has over 15 years’ experience in business development gained from roles in both biotech and pharma. Since joining F-star in late 2011 Jane has led a series of significant and innovative transactions with BMS, AbbVie, Denali and Merck (EMD Serono) raising almost $200M in non-dilutive financing and advancing F-star’s drug pipeline. By establishing asset-centric-vehicles as well as more traditional licensing, F-star has been able to realise the value of its individual assets through flexible deal structuring. As well as business development, Jane is responsible for transactional legal matters, IP and Communications at F-star. Earlier this year she was identified by Labiotech as one of the 15 Women Leading in European Biotech.
Prior to F-star, she held business development positions at Cellzome and Cambridge Antibody Technology (CAT). At Cellzome she led two significant transactions with GSK; Cellzome was subsequently acquired by GSK in 2012. During her time at CAT she led negotiations on multiple significant transactions, subsequently continuing this work within AstraZeneca following the acquisition of CAT.
She has a first class degree, a PhD and an MBA from the University of Cambridge and spent the first part of her career within the agrochemical industry. She is Vice-Chair of the Sir Richard Stapley Educational Trust, a member of the University of Cambridge Careers Service Syndicate and an Associate of Newnham College.
Dr Darrin Disley
Darrin is a scientist who has been involved in the start-up and growth of numerous business ventures. He has a track record of securing over $270 million business financing from grant, angel, corporate, venture capital and public market sources as well as closing over $400 million of product, service, licensing and M&A deals. In 2012, he was named Business Leader of the Year at the European Life Science Awards, in 2014 was named Executive of the Year by Scrip a global award recognising leadership in biotechnology and pharmaceutical companies and in 2015 was named UK Quoted Company Entrepreneur of the Year, Cambridge Business Person of the Year and one of the 175 Faces of Chemistry by the Royal Society of Chemistry.
In 2014 Darrin listed Horizon Discovery Group plc on the AIM market of the London Stock Exchange achieving a placement of $113 million, an all-time record for a life science company on AIM and the largest ever from the Cambridge cluster. Since the IPO, Darrin has completed a secondary placement of $60 million and several M&A transactions including the combination screening services business CombinatoRx based in Cambridge, Massachusetts, the world-leading in vivo gene-editing business SAGE Labs based in St Louis, Missouri and Boyertown, Pennsylvania and Haplogen Genomics GmbH a genomics company based in Vienna, Austria.
Professor Jackie Hunter
Benevolent Bio and BenevolentAI use AI to augment the research capabilities of drug scientists, radically changing the way R&D is done. She has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. In that role she oversaw the entry of over 20 compounds into clinical studies and the conduct of 17 Proofs of Concept. She has served on numerous academic, industry and government Boards and panels in both Europe and America e.g. in the establishment of the Innovative Medicines Initiative (IMI), a 2B euro public-private partnership between the pharmaceutical industry and the European Commission. She served on the IMI Board and was Chair of the EFPIA Research Directors Group.
She founded OI Pharma Partners in 2010 to support the life science sector in harnessing the power of open innovation working with a variety of organizations, including the establishment of an Open Innovation Strategy for the Cyprus Presidency of the EU. For 3 years she was the CEO of the BBSRC which distributes approximately £500M p.a for bioscience research and its translation. She holds a personal chair from St George's Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. She was also awarded a CBE in 2010 for Services to the Pharmaceutical Industry.
Dr Kyriacos Mitrophanous
Oxford BioMedica is a leading Gene and Cell therapy company that focuses on developing novel treatments in the areas of CNS, Ocular and Oncology. Kyriacos’ focus has been the research and development of lentiviral vectors for clinical applications including neurological disorders comprising Parkinson’s disease and Motor neuron disease; ophthalmic disorders including wet-AMD, Usher syndrome and Stargardt disease; and in oncology. This work has been extensively published in leading peer reviewed journals. He was appointed Chief Scientific Officer at Oxford BioMedica in 2014 and is a member of the British, European and American gene therapy associations (BSGCT, ESGCT, ASGCT) and of the BIA Cell Therapy and Regen Med Advisory Committee.
Kyriacos obtained his PhD in Molecular Biology from the University of London in 1996. Following this he moved to the Department of Biochemistry, Oxford University where he conducted postdoctoral research into the development of viral based vectors for gene therapy. He joined Oxford BioMedica in 1997, following its spinout from Oxford University.
In the last few years a number of such therapies have received market authorisation with the latest being Novartis’ Kymriah™ (CTL019) for the treatment of B-cell precursor acute lymphoblastic leukaemia approved by the FDA in August 2017. Oxford BioMedica is sole manufacturer of the vector for this product.
Brenda is currently CEO of Calchan, a Biotech company specialising in new medicines for pain and inflammation. Calchan operates according to a virtual model using a network of consultants, advisors and CRO’s. Prior to this she was a founder of Convergence, a pain company acquired by Biogen, and a founder and COO of Powdermed, managing its inception through to its sale in 2006 and subsequent integration into Pfizer.
She has advised a number of life science companies along the way as both a consultant or NED. In parallel she has mentored and continues to mentor some early spin-outs. She originally qualified as a Toxicologist and has subsequently become a Chartered Director and Fellow of the IOD.
Much of her earlier career was spent managing global projects for large Pharmaceutical companies. This has given her a good insight into the complexities and challenges of translational medicine across a number of therapeutic areas. It has also given her an appreciation of the importance of getting people onside for successful project delivery. Whoever said “People are your greatest asset” were absolutely right and she has always tried to create an environment in which they flourish.
She is keen to put some of her knowledge and skills to good use in supporting the development of potential new young leaders. She feels it is critical that we expand the pool of potential CEO’s and other senior executives to underpin growth in the Biotech sector.
Dedicated to building the Cell and Gene Therapy industry in the UK, he has established a team of over 140 cell and gene therapy experts, in state-of-the-art laboratories in London, and a unique large-scale manufacturing Centre in Stevenage, to accelerate industry growth.
Starting out in the new field of monoclonal antibodies in 1979, he soon moved into the new Bio-industry at GD Searle. He was Managing Director of Bioscot, Scotland’s first Biotechnology company, manufacturing monoclonal antibodies for transfusion medicine and, in 1993 received the Queen’s Award for export; at NASDAQ-listed Serologicals he was Vice President of Diagnostics Operations where he grew the business to over $100m sales of reagents and cell culture media components before becoming Vice President of Global Manufacturing. Serologicals sold to Millipore for $1.4bn in 2006. He was the National Director of the Scottish Blood Transfusion Service, where he focused on modernising the blood supply and expanding into cell therapy. During that period, he formed and privatised the NHS diagnostics company Alba Bioscience, now NASDAQ-listed Quotient. He also steered SNBTS through the challenge of vCJD in the blood supply, and a public inquiry into historical HIV and Hepatitis C infections.
He has brought significant manufacturing and commercial experience to the BIA Board. In addition, experience of running a part of the NHS and working with the highest levels of Government.
Dr Will West
Will is Executive Chairman of CellCentric Ltd, an epigenetic-based cancer drug discovery and development company, originally spun out of Cambridge University. The lead product is a small molecule inhibitor of p300/CBP for prostate cancer (CRPC), as well as other tumours with specific p300 or CBP mutations (bladder, lung, haem). Additionally, Will is President & CEO of CTS Inc., a non-viral gene product, cancer imaging and treatment business founded out of Johns Hopkins School of Medicine, Baltimore.
Will gained a PhD in Immunology and Virology sponsored by Unilever (UniPath), before holding a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC). He went on to Procter & Gamble Healthcare, where he was responsible for clinical development in a number of therapeutic areas, including respiratory and GI. Will holds a Masters degree in Clinical Research as well as an MBA from London Business School.
Will is on the Board and Executive Committee of the BIA. Previously he was on the Council of the BBSRC, which distributes £500m a year on bioscience research on behalf of the Government. He is a co-founder of Angels 4 Life Sciences, an investor forum which works closely with Angels in MedCity.
Dr Celia Caulcott
Celia trained initially in microbiology and following her PhD she joined Celltech, where she worked on therapeutic recombinant monoclonal antibodies. After working for ICI Pharmaceuticals and the Wellcome Foundation, she became an independent bio-pharmaceutical and research management consultant, working on projects for the then DTI, the Food Standards Agency and the Department of Health, as well as for the BBSRC and MRC. She also worked for the Wellcome Trust on the Pathogen Genome Sequencing Programme and the Human Genome Project, and for Imperial College London developing research strategy.
At the BBSRC, Celia had responsibility for leading the innovation strategy of the Council, including for BBSRC campuses. She led on BBSRC engagement with industry, interactions with InnovateUK and the funding of collaborative research with a variety of partners, and also skills. She was also the Executive Lead for the BBSRC Industrial Biotechnology strategy, and worked closely with other funding bodies to deliver bioscience research to support the bioeconomy.
Celia moved to UCL as the Vice-Provost, Enterprise in 2015. She has responsibility for development and oversight of the UCL strategy for enterprise and innovation, as well as being a board member of UCLBusiness and involvement in other enterprise activities.
Sue leads the global Life Sciences practice of Instinctif Partners, a leading business communications consultancy.
Having been actively involved with the biotech sector for some three decades, Sue is passionate about helping the UK’s strengths in bioscience innovation translate into commercial and investor success. Her global experience spans advising early stage private to large multinational companies, seeing clients through periods of celebration and challenge, and supporting successful financings both privately and on public markets. She has also provided communications counsel to academic and not-for-profit organisations as well as numerous venture funds. She has contributed to initiatives to encourage the development of talent including as a supporter of BiotechYES and as founder of the ‘Career Alternatives for Scientists’ initiative.
A current member of the BIA Board, Sue is an entrepreneur and business leader who has founded and sold three communications consultancies, an experienced CEO of a biotech spin-out and holder of non-executive positions. Sue was named as one of most inspirational women working in Life Sciences in in 2016 and again in 2017.
Sue has a first class degree in Biochemistry from Oxford and an MBA from Cranfield Business School.
Dr Dan Mahony
Daniel Mahony is a portfolio manager at Polar Capital. He studied biochemistry at the University of Oxford and received his Ph.D. from the University of Cambridge. Daniel moved to California to work as a research scientist at Schering Plough Corporation (now Merck & Co.) in 1995 and made the transition into financial services in 1998, working for ING Barings in New York and Morgan Stanley in London as head of the European healthcare research team. In 2007, he set up Polar Capital’s healthcare team. He has over 23 years of experience within global healthcare covering sectors including biotechnology, medical technology and healthcare services.
Diana is a patent litigator with particular expertise in biotechnology patents.
As well as acting in all UK courts, she advises on international disputes and coordinate and assist with actions in other jurisdictions and patent offices. Her patent career began with the land mark case of Biogen against Medeva and in 2015 and she chaired a Reunion of the people involved to celebrate the 20th anniversary. Since that case she has acted in many significant cases, in particular, in the life sciences sector.
She is an active participant in the BIA and has been a member of the Board since 2011, she is also a member of the Executive Committee of the Board assisting in the operational oversight of the Association. She is an Associate Member of the Chartered Institute of Patent Attorneys and an accredited mediator.
Lord David Willetts
Lord Willetts is Executive Chair of the Resolution Foundation and former Minister for Universities and Science. He was MP for Havant from 1992-2015, and stood down ahead of the 2015 General Election. Before becoming an MP, he worked in HM Treasury and the Number 10 Policy Unit, before becoming Director of the Centre for Policy Studies.
Lord Willetts has taken on a number of science- and policy-linked commitments. He is a Council Member of the Institute for Fiscal Studies, a Governor of the Ditchley Foundation and a Board Member of the National Institute of Economic and Social Research. He has written widely on economic and social policy and continues to write and speak on these topics. His book 'A University Education' was published in November 2017. He has maintained strong links with the scientific community, as Chair of the British Science Association and a board member of both the Francis Crick Institute and the Science Museum. Lord Willetts is also involved in innovation through non-executive directorships of Surrey Satellite Technology and the Biotech Growth Trust.
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.
A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.
Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.
Nick is responsible for overseeing the BIA’s operations, ensuring that all activities are professionally delivered to the highest standard. He will be providing an organisation-wide operational perspective to, and support for, activities and projects.
He has specific responsibility for office management/facilities, financial systems/processes and credit control, company secretariat, human resources and IT/telecoms. Nick joined the BIA in October 2014, bringing with him extensive industry and not-for-profit management experience.
Prior to this role he ran the Clinical Laboratory Division of Lab21. This involved providing specialist laboratory services to the healthcare, pharmaceutical and clinical trials markets. He had management responsibility for all operations, income, laboratory and customer services and client liaison across the Group. He also has specific experience of diagnostic testing within the HIV and HCV disease areas. This was gained through building Delphic Diagnostics into a one-stop-shop for clinicians, enabling more effective patient monitoring and subsequent treatment options.
Nick also has extensive management experience within the not-for-profit sector, working for a trade body representing and building the profile of the business communication industry.